Anti-Infective Agents Market Size, Share, Growth and Forecast (2026 - 2036)

Anti-Infective Agents Market Forecast and Outlook By FACT MR

• The anti-infective agents market was valued at USD 154 billion in 2025. Fact.MR estimates the market will reach USD 158 billion in 2026 and expand further to nearly USD 208 billion by 2036. The industry is projected to grow at a CAGR of 2.8% during the forecast period.
• The market is projected to create an incremental revenue opportunity of around USD 50 billion between 2026 and 2036.
• Demand growth is supported by rising infectious disease cases in developing healthcare systems and higher treatment needs for hospital-acquired infections.
• National HIV and tuberculosis control programs also create steady long-term demand for anti-infective therapies. Antimicrobial resistance and the high cost of developing new anti-infective drugs continue to limit faster market expansion.

Summary of Anti-Infective Agents Market

• Demand Drivers
  • Rising hospital-acquired infection are increasing demand for IV antibacterial therapies in hospitals. Drug-resistant bacterial infections continue to create a major treatment burden globally.
  • National HIV and tuberculosis treatment programs support steady long-term demand fir anti-infective prescription in high-burden countries. Antiviral therapy use remains strong as treatment coverage improves.
  • Outpatient respiratory infection treatment is increasing through retail and specialty pharmacies. Telehealth expansion is also improving access to oral broad-spectrum anti-infective therapies in developed and emerging healthcare markets.
• Key Segments Analyzed
  • By Type: Antibacterial agents hold 42% share in 2026 because bacterial infection treatment continues generating the significant prescription volume across hospitals and outpatient healthcare settings.
  • By Range: Broad spectrum products account for 58% share in 2026 due to increasing empirical treatment use for respiratory and hospital-acquired infections.
  • By Route of Administration: Oral formulations capture 46% share in 2026 as outpatient infectious disease management remains strongly dependent on oral therapies.
  • By Indication: Respiratory infections hold 31% share in 2026 due to high incidence of seasonal and healthcare-associated respiratory diseases worldwide.
  • By Distribution Channel: Hospital pharmacies account for 39% share in 2026 since severe infectious disease treatment and IV anti-infective administration mainly occur in institutional care settings.
• Analyst Opinion at Fact.MR
  • Shambhu Nath Jha, Principal Consultant at Fact.MR, opines, 'CXOs will observe that the anti-infective agents market is gradually shifting from volume-based competition toward differentiated therapies targeting antimicrobial resistance. Antibacterial pipeline strength and hospital formulary positioning are becoming increasingly important for long-term revenue growth.'
• Strategic Implications
  • Pharmaceutical companies should focus more on antibacterial and antifungal therapies for hospital programs. Drug-resistant infection coverage is becoming a major purchasing factor across institutional healthcare systems.
  • Companies should expand oral broad-spectrum anti-infective portfolios for outpatient and telehealth prescription channels. Respiratory infection treatment demand continues rising across North America and Europe.
  • Organizations should build stronger specialty pharmacy and e-commerce partnerships for HIV and hepatitis antiviral therapies. Adherence support programs help improve patient retention and repeat prescription.

The United States is projected to grow at 7.3% CAGR through 2036, supported by hospital pharmacy networks and federal antimicrobial stewardship programs. The United Kingdom is expected to record 6.8% CAGR as NHS infection control protocols support inpatient IV anti-infectives and specialty drug access. Germany follows at 6.2% CAGR due to wider reimbursement for novel antibacterials under statutory health insurance. France is likely to advance at 5.9% CAGR as regulated hospital formularies add drugs for resistant pathogen coverage. Italy is forecast to register 5.5% CAGR as national infection management frameworks update public hospital treatment guidelines.

Segmental Analysis

Anti-Infective Agents Market Analysis by Type

Antibacterial agents hold 42% share in 2026 as bacterial infection treatment continues to generate significant prescription volume globally. Hospitals and outpatient clinics reply on antibacterial therapies for many infectious disease treatments. Gilead Sciences signed royalty-free licensing agreements with six generic manufacturers to expand access to lenacapavir for HIV prevention across 120 resource-limited countries. [1] This supports wider access to long-acting anti-infective therapies and strengthens global HIV prevention programs.

• Resistance-targeting Development: Pharmaceutical companies continue to expand antibacterial pipelines focused on resistant pathogen treatment.
• Antifungal Therapy Growth: Hospitals are increasing adoption of advanced antifungal therapies due to rising fungal infection incidence among immunocompromised patients.
• Antiviral Access Expansion: Global HIV treatment programs continue increasing antiviral therapy coverage across high-burden countries.

Anti-Infective Agents Market Analysis by Range

Broad spectrum products account for 58% share in 2026 because physicians often start treatment before pathogen confirmation. Respiratory and hospital-acquired infections continue to support strong empirical treatment demand.  SCYNEXIS advanced development of its next-generation antifungal candidate SCY-247 for invasive candidiasis and drug-resistant fungal infections following positive Phase 1 study results. The company also highlighted continued progress in antifungal therapies through its partnership with GSK and the planned relaunch of BREXAFEMME. [2]

• Empirical Treatment Preference: Hospitals continue prioritizing broad-spectrum therapies for sepsis and severe infection management.
• Generic Product Availability: Broad-spectrum anti-infective generics remain widely prescribed due to lower treatment cost and large-scale availability.
• Narrow-spectrum Stewardship Growth: Antimicrobial stewardship programs are gradually increasing use of targeted narrow-spectrum therapies after laboratory confirmation.

Anti-Infective Agents Market Analysis by Route of Administration

Oral formulations capture 46% share in 2026 as outpatient infectious treatment depends heavily on oral medicines. Convenience and patient compliance continue to support oral anti-infective demand. Wockhardt announced that the US FDA accepted the NDA for its novel antibiotic Zaynich, developed to treat multidrug-resistant and extensively drug-resistant bacterial infections. It also received Fast Track designation, supporting demand for advanced anti-infective therapies against antimicrobial resistance. [3]

• Telehealth Prescription Expansion: Telehealth platforms continue to increase prescription volume for oral respiratory infection therapies.
• Long-acting Injectable Growth: HIV treatment programs are gradually increasing adoption of long-acting injectable antiviral therapies.
• IV Therapy Demand: Intensive care units continue to increase demand for IV anti-infective treatment for resistant infections.

Anti-Infective Agents Market Analysis by Indication

Respiratory infections hold 31% share in 2026 due to high cases of seasonal and hospital-related respiratory diseases. Hospital-acquired respiratory infections also continue to support prescription demand. Gilead Sciences announced expanded access planning for lenacapavir HIV prevention in low- and middle-income countries through royalty-free licensing, no-profit supply programs, and accelerated regulatory pathways. The initiative supports wider adoption of long-acting anti-infective therapies and strengthens global HIV prevention efforts across high-incidence regions. [4]

• Antiviral Respiratory Demand: Respiratory antiviral therapy usage remains elevated across high-risk patient groups.
• Tuberculosis Program Expansion: Global tuberculosis treatment funding continue to increase antibacterial therapy demand across high-burden regions.
• HIV Therapy Stability: Long-term HIV treatment programs continue to support stable antiviral prescription volumes globally.

Anti-Infective Agents Market Analysis by Distribution Channel

Hospital pharmacies account for 39% share in 2026 as severe infectious treatment and IV therapy mainly happen in hospitals. Large hospital systems continue to control high-value and anti-infective purchasing decisions. ViiV Healthcare highlighted continued expansion of long-acting injectable

• Specialty Pharmacy Expansion: Specialty pharmacy networks continue increasing distribution of HIV and advanced antiviral therapies.
• E-commerce Growth: Online pharmacy platforms are gradually increasing outpatient dispensing of oral anti-infective generics.
• Retail Pharmacy Demand: Retail pharmacy chains continue reporting strong prescription volume growth for oral antibacterial and respiratory infection therapies.

Drivers, Restraints, and Opportunities

The anti-infective agents market is expanding due to rising infectious disease burden and increasing treatment in hospital and outpatient care.

Antiviral therapy programs and drug-resistant infection treatment are changing prescription patterns in global healthcare systems. Cabenuva for HIV treatment, supporting improved adherence and reduced dosing frequency for patients. The development strengthens growth in advanced anti-infective therapies focused on long-acting HIV management and patient-centric drug delivery solutions. [5]

• Antiviral Therapy Expansion: National HIV and chronic infectious disease programs continue supporting long-term antiviral prescription demand across developing healthcare markets.
• Outpatient Prescription Growth: Telehealth therapy expansion and retail pharmacy access are increasing oral anti-infective prescription volumes for respiratory and community-acquired infections.
• Generic Pricing Pressure: Commodity antibacterial products continue facing pricing pressure due to large-scale generic competition across mature pharmaceutical markets.

Regional Analysis

The anti-infective agents market is assessed across North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa, covering 40+ country-level demand by drug type, administration route, indication, and distribution channel. The full report includes market attractiveness analysis by region and country.

Source: Fact.MR analysis, based on proprietary forecasting model and primary research

North America Anti-Infective Agents Market Analysis

North America is the leading region for per-capita spending on anti-infective therapies due to advanced hospital infrastructure and large institutional purchasing programs. Rising antimicrobial resistance and growing demand for specialty antiviral therapies continue supporting strong market value across the region.

• United States: The United States is projected to grow at 7.3% CAGR. Federal antimicrobial resistance programs are increasing hospital use of advanced antibacterial therapies. Academic medical centers and intensive care units are using more reserve-class IV antibacterials for multidrug-resistant infections. Telehealth growth is also increasing outpatient prescription volume for oral respiratory anti-infective therapies across retail and specialty pharmacy channels.

Europe Anti-Infective Agents Market Analysis

Europe has a highly regulated antimicrobial stewardship environments. National healthcare authorities control formulary access through reimbursement approvals and prescription monitoring programs.

• United Kingdom: The United Kingdom is projected to grow at 6.8% CAGR by 2036. NHS antimicrobial stewardship programs are increasing demand for reserve antibiotics in acute care hospitals. HIV antiviral access is expanding through specialty pharmacy programs and national sexual health services. Hospital systems remain focused on reducing inappropriate broad-spectrum antibiotic market.
• France: France is expected to expand at 5.9% CAGR till 2036. National antimicrobial resistance programs are supporting hospital use of advanced antibacterial resistant pathogens in intensive care and emergency care settings. Hospitals are also increasing investment in antifungal therapies for immunocompromised patient management.
• Germany: Germany is forecast to grow at 6.2% CAGR. Expanded reimbursement support for novel antibacterial therapies is improving hospital formulary access in university medical centers and specialist infection units. Demand for targeted therapies is rising due to resistant bacterial infection cases.
• Italy: Italy is projected to grow at 5.5% CAGR. Public hospitals are using more advanced antifungal and antibacterial therapies in hematology and transplant care programs. National reimbursement updates are also supporting wider access to modern anti-infective treatments.

Competitive Aligners for Market Players

Anti-infective drug manufacturers are shifting focus toward antibacterial and antifungal therapies for drug-resistant infections. Hospital formularies now give more weight to treatments for multidrug-resistant infections in intensive care and inpatient settings. Companies with advanced antibacterial pipelines are improving their position in institutional healthcare markets.

Antiviral therapy programs continue representing another major growth area across long-term infectious disease diagnostic. HIV and hepatitis antiviral demand stays stable due to national treatment programs and specialty pharmacy networks. Manufacturers with strong antiviral portfolios and global supply relationships have better recurring revenue visibility.

Oral broad-spectrum anti-infective products continue to generate high outpatient prescription volume in North America and Europe. Telehealth expansion and retail pharmacy access are raising demand for community-based respiratory infection treatment. Companies building digital pharmacy partnerships can improve outpatient distribution. Hospital formulary positioning is becoming more important for premium anti-infective therapies. Institutional reimbursement approval and antimicrobial stewardship alignment now influence purchasing decisions across major healthcare systems. Manufacturers investing in clinical evidence for resistant pathogen coverage and lower hospitalization risk can strengthen long-term competitiveness in developed pharmaceutical markets.

Key Players

• Pfizer Inc.
• Gilead Sciences, Inc.
• Merck & Co., Inc.
• Johnson & Johnson Innovative Medicine
• AbbVie Inc.

Bibliography

• [1] Gilead Sciences, Inc. (2024, October 2). Gilead signs royalty-free voluntary licensing agreements with six generic manufacturers to increase access to lenacapavir for HIV prevention in high-incidence, resource-limited countries.
• [2] SCYNEXIS, Inc. (2025, November 5). SCYNEXIS reports third quarter 2025 financial results and provides corporate update.
• [3] Wockhardt Limited. (2025, December 1). US FDA accepts Wockhardt’s New Drug Application for breakthrough antibiotic Zaynich.
• [4] Gilead Sciences, Inc. (2025, June 18). Gilead statement on access planning for lenacapavir for HIV prevention in low- and middle-income countries.
• [5] ViiV Healthcare. (2026, February 24). ViiV Healthcare reports long-acting injectable Cabenuva effectively maintains viral suppression in adolescents living with HIV, with >97% preferring injections over daily oral treatment.

This Report Addresses

• Strategic analysis of anti-infective agent demand across hospital-acquired infection treatment, HIV antiviral therapy, tuberculosis programs, outpatient respiratory infection management, and telehealth-driven prescription channels.
• Market forecast from USD 158 billion in 2026 to USD 208 billion by 2036 at 2.8% CAGR, including segment-level growth analysis by type, range, route, indication, and distribution channel.
• Opportunity assessment across the United States, United Kingdom, Germany, France, and Italy based on antimicrobial stewardship policies, formulary reimbursement rules, and national infectious disease program investment.
• Segment analysis by drug type, spectrum range, route of administration, indication, and distribution channel with regional and country-level forecasts till 2036.
• Competitive analysis of Pfizer, Gilead Sciences, GlaxoSmithKline, Merck, and Johnson & Johnson Innovative Medicine covering resistance-targeting pipeline strength, formulary positioning, specialty pharmacy access, and antiviral therapy market presence.
• Regulatory impact analysis covering WHO AMR action plans, national antimicrobial stewardship mandates, EMA and FDA approval pathways for novel anti-infectives, and reimbursement rule changes across key markets.
• Report delivery in PDF, Excel, and presentation formats supported by pharmaceutical company filings, national drug procurement records, and primary interviews with clinical and commercial stakeholders.

Anti-Infective Agents Market Definition

The anti-infective agents market covers pharmaceutical compounds used to treat infections caused by bacteria, viruses, fungi, and other pathogens. These agents act by inhibiting pathogen growth, disrupting cellular function, or blocking replication mechanisms. They are prescribed across hospital, outpatient, and specialty care settings for indications ranging from common respiratory infections to HIV and drug-resistant tuberculosis.

Anti-Infective Agents Market Inclusions

Covers global and regional market forecasts from 2026 to 2036 by type, spectrum range, route of administration, indication, and distribution channel. Includes antibacterial, antiviral, antifungal, and other classes across IV, oral, and topical delivery forms for hospital pharmacy, retail pharmacy, specialty pharmacy, and e-commerce channels.

Anti-Infective Agents Market Exclusions

Excludes antiparasitic agents and vaccines not classified as anti-infective drug compounds. Omits raw active pharmaceutical ingredient (API) trade volumes not tied to finished formulation revenue. Excludes hospital infection control equipment, diagnostic test kits, and sterilization products. Downstream insurance reimbursement flows and non-prescription disinfectant retail products are also outside scope.

Anti-Infective Agents Market Research Methodology

• Primary Research
  • Interviews with hospital pharmacists, infectious disease physicians, generic drug manufacturers, specialty pharmacy directors, and institutional formulary managers across the United States, United Kingdom, Germany, France, and Italy.
• Desk Research
  • Analysis of Pfizer, Gilead Sciences, GlaxoSmithKline, Merck, and Johnson & Johnson Innovative Medicine public filings and earnings transcripts. Supplemented by WHO antimicrobial resistance data, CDC antibiotic use tracking, EMA approval databases, and national health ministry reimbursement records.
• Market-Sizing and Forecasting
  • Hybrid model combining top-down pharmaceutical company anti-infective revenue disclosures with bottom-up prescription volume estimates by indication and delivery route, cross-referenced with average selling prices by drug class and distribution channel.
• Data Validation and Update Cycle
  • Validated through national drug regulatory approval records, hospital formulary procurement databases, WHO essential medicine list updates, and earnings-disclosed anti-infective segment revenues. Updated annually with approval data and drug pricing changes.